UBS Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Cuts Target Price to $14
A Quick Look at Today's Ratings for Avadel Pharmaceuticals(AVDL.US), With a Forecast Between $13 to $22
Avadel Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Avadel Pharmaceuticals Price Target Cut to $13.00/Share From $24.00 by Piper Sandler
Avadel Pharmaceuticals Down Nearly 31%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and ProQR (PRQR)
